Supplementary Materials
infection
PROLIFERATION, INFECTION, DISEASE
Table S1: demographics and characteristics of SLE patients in miRNA sequencing. Table S2: demographics and characteristics of SLE patients for validation of miRNA candidates. Table S3: primers for reverse transcription and real-time polymerase chain reaction. Figure S1: the heatmap (a) and volcano plot (b) of differentially expressed miRNAs in SLE patients before and after receiving MSCT. Figure S2: the infection of PBMCs with shMAP3K1 lentivirus.Click here for additional data file.Total miRNA expressions detected in the small RNA sequencing analysis of pre- and post-MSCT group.Click here for additional data file.The differentially expressed miRNAs between pre- and post-MSCT group.Click here for additional data file.Circulating miR-320b is decreased after MSCT in SLE patients and associated with disease activity. (a) miR-320b expression in plasma and PBMCs of SLE patients before and after receiving MSCT. Plasma, MAP3K1 is a target of miR-320b. (a) The KEGG pathway analysis of predicted target genes of miR-320b. (b) HEK293T was transfected with mimics of miR-320b for 48 hr. MAP3K1 mRNA abundance was measured using qRT-PCR. (c) Protein levels were assessed using Western blot. (d) Sequence analysis of human miR-320b and MAP3K1 mRNA 3′-UTR. The predicted binding regions are highlighted in red. (e) Luciferase activity assays were performed to assess whether the regulatory effect of hsa-miR-320b requires the predicted binding sites in the MAP3K1 mRNA 3′-UTR in HEK293T cells. For miR-320b, the respective binding sites were individually mutated in pMIR1286 (Mutant1), pMIR1758 (Mutant2), and both two sites (Mutant3). Decreased MAP3K1 level in SLE PBMCs is involved in CD4+ T-cell proliferation. (a) The MAP3K1 expression in PBMCs and ROC curve of HC and SLE groups. HC, miR-320b blockade alleviates symptoms of SLE and inhibits proliferation of CD4+ T cells in MRL/MSCs regulate miR-320b/MAP3K1 expression both 